DK1557414T3 - IsoquinoIin-forbindelser og medicinsk anvendelse deraf - Google Patents
IsoquinoIin-forbindelser og medicinsk anvendelse derafInfo
- Publication number
- DK1557414T3 DK1557414T3 DK03748659.4T DK03748659T DK1557414T3 DK 1557414 T3 DK1557414 T3 DK 1557414T3 DK 03748659 T DK03748659 T DK 03748659T DK 1557414 T3 DK1557414 T3 DK 1557414T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- cerebral infarction
- agent
- prophylaxis
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010008118 cerebral infarction Diseases 0.000 abstract 4
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 206010060860 Neurological symptom Diseases 0.000 abstract 1
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000035874 hyperreactivity Effects 0.000 abstract 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 abstract 1
- -1 isoquinoline compound Chemical class 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002288833 | 2002-10-01 | ||
| JP2002340175 | 2002-11-22 | ||
| JP2003109160 | 2003-04-14 | ||
| PCT/JP2003/012608 WO2004031171A1 (ja) | 2002-10-01 | 2003-10-01 | イソキノリン化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1557414T3 true DK1557414T3 (da) | 2012-05-29 |
Family
ID=32074144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03748659.4T DK1557414T3 (da) | 2002-10-01 | 2003-10-01 | IsoquinoIin-forbindelser og medicinsk anvendelse deraf |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7220759B2 (enExample) |
| EP (1) | EP1557414B1 (enExample) |
| JP (1) | JP4520406B2 (enExample) |
| KR (1) | KR100735781B1 (enExample) |
| CN (1) | CN100390164C (enExample) |
| AT (1) | ATE552252T1 (enExample) |
| CA (1) | CA2500888C (enExample) |
| DK (1) | DK1557414T3 (enExample) |
| ES (1) | ES2380917T3 (enExample) |
| PT (1) | PT1557414E (enExample) |
| TW (1) | TW200424188A (enExample) |
| WO (1) | WO2004031171A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100390164C (zh) * | 2002-10-01 | 2008-05-28 | 三菱制药株式会社 | 异喹啉化合物及其医药用途 |
| CA2507027C (en) * | 2002-11-22 | 2012-05-08 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| EP2184282B1 (en) | 2007-08-10 | 2014-10-08 | Mitsubishi Tanabe Pharma Corporation | Novel salt of isoquinoline compound and crystal thereof |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| US9173395B2 (en) | 2011-07-04 | 2015-11-03 | Bayer Intellectual Property Gmbh | Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| WO2013132253A1 (en) * | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP3044221B1 (en) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| AR098776A1 (es) * | 2013-12-18 | 2016-06-15 | Chiesi Farm Spa | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas |
| KR102293986B1 (ko) * | 2019-10-30 | 2021-08-26 | 충남대학교산학협력단 | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US12496297B1 (en) * | 2020-10-23 | 2025-12-16 | Washington University | Compositions of autophagy modulating agents and uses thereof |
| CN113636970B (zh) * | 2021-09-13 | 2023-05-23 | 河北康泰药业有限公司 | 一种异吲哚酮的化合物、制备方法及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1062357A (en) | 1912-05-31 | 1913-05-20 | Warschauer Schrauben Und Drahtfabriken Ag | Nut-lock. |
| US1174272A (en) | 1915-10-27 | 1916-03-07 | Commw Steel | Locomotive-bed. |
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| JPS4612454Y1 (enExample) * | 1968-07-26 | 1971-04-30 | ||
| DE2121031A1 (en) | 1971-04-29 | 1972-11-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Base-substd quinazolines - thrombocyte aggregation inhibitors |
| IT1054655B (it) * | 1975-08-27 | 1981-11-30 | Lepetit Spa | Derivati condensati del l isochinolina |
| JPS52156875A (en) | 1976-06-23 | 1977-12-27 | Mitsui Toatsu Chem Inc | Preparation of novel isoquinolone derivatives |
| JPS5484597A (en) | 1977-12-15 | 1979-07-05 | Yamanouchi Pharmaceut Co Ltd | Novel heterocyclic compound and its preparation |
| JPS6442472U (enExample) | 1986-06-14 | 1989-03-14 | ||
| US4808595A (en) | 1986-12-24 | 1989-02-28 | Merck & Co., Inc. | Furopyridine sulfonamides and their opthalmological compositions |
| JPS6442472A (en) | 1987-08-10 | 1989-02-14 | Kanebo Ltd | Quinazoline derivative, production thereof and brain function disorder improving agent containing said derivative as active ingredient |
| DE68920798T2 (de) | 1988-08-19 | 1995-05-18 | Warner Lambert Co | Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren. |
| AU8784698A (en) | 1997-08-15 | 1999-03-08 | Johns Hopkins University, The | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| WO1999059973A1 (en) * | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| WO2000042025A1 (en) | 1999-01-14 | 2000-07-20 | Meiji Seika Kaisha, Ltd. | Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives |
| KR20010101675A (ko) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| WO2001079184A1 (en) | 2000-04-18 | 2001-10-25 | Sumitomo Pharmaceuticals Company, Limited | Substituted piperazine compounds |
| WO2002044157A2 (en) | 2000-12-01 | 2002-06-06 | Iconix Pharmaceuticals, Inc. | Parb inhibitors |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| CN100390164C (zh) * | 2002-10-01 | 2008-05-28 | 三菱制药株式会社 | 异喹啉化合物及其医药用途 |
| CA2507027C (en) | 2002-11-22 | 2012-05-08 | Mitsubishi Pharma Corporation | Isoquinoline compounds and medicinal use thereof |
| JP4612454B2 (ja) | 2005-03-31 | 2011-01-12 | 本田技研工業株式会社 | ブレーキ制御装置 |
-
2003
- 2003-10-01 CN CNB200380100827XA patent/CN100390164C/zh not_active Expired - Fee Related
- 2003-10-01 WO PCT/JP2003/012608 patent/WO2004031171A1/ja not_active Ceased
- 2003-10-01 EP EP03748659A patent/EP1557414B1/en not_active Expired - Lifetime
- 2003-10-01 AT AT03748659T patent/ATE552252T1/de active
- 2003-10-01 JP JP2005500092A patent/JP4520406B2/ja not_active Expired - Fee Related
- 2003-10-01 DK DK03748659.4T patent/DK1557414T3/da active
- 2003-10-01 TW TW092127338A patent/TW200424188A/zh not_active IP Right Cessation
- 2003-10-01 CA CA2500888A patent/CA2500888C/en not_active Expired - Fee Related
- 2003-10-01 PT PT03748659T patent/PT1557414E/pt unknown
- 2003-10-01 KR KR1020057005596A patent/KR100735781B1/ko not_active Expired - Fee Related
- 2003-10-01 ES ES03748659T patent/ES2380917T3/es not_active Expired - Lifetime
-
2004
- 2004-04-30 US US10/836,377 patent/US7220759B2/en not_active Expired - Lifetime
-
2007
- 2007-03-19 US US11/688,103 patent/US7459465B2/en not_active Expired - Lifetime
-
2008
- 2008-11-03 US US12/263,963 patent/US7812178B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2500888A1 (en) | 2004-04-15 |
| US7459465B2 (en) | 2008-12-02 |
| ATE552252T1 (de) | 2012-04-15 |
| US20040248931A1 (en) | 2004-12-09 |
| EP1557414A1 (en) | 2005-07-27 |
| US7220759B2 (en) | 2007-05-22 |
| TW200424188A (en) | 2004-11-16 |
| US7812178B2 (en) | 2010-10-12 |
| JPWO2004031171A1 (ja) | 2006-02-02 |
| WO2004031171A1 (ja) | 2004-04-15 |
| CA2500888C (en) | 2010-07-13 |
| US20090076276A1 (en) | 2009-03-19 |
| US20070161620A1 (en) | 2007-07-12 |
| KR20050070024A (ko) | 2005-07-05 |
| CN1703410A (zh) | 2005-11-30 |
| AU2003268724A1 (en) | 2004-04-23 |
| ES2380917T3 (es) | 2012-05-21 |
| CN100390164C (zh) | 2008-05-28 |
| JP4520406B2 (ja) | 2010-08-04 |
| EP1557414B1 (en) | 2012-04-04 |
| KR100735781B1 (ko) | 2007-07-06 |
| PT1557414E (pt) | 2012-04-17 |
| TWI338687B (enExample) | 2011-03-11 |
| EP1557414A4 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI348371B (enExample) | ||
| GB0225475D0 (en) | Therapeutic agents | |
| GB0318447D0 (en) | Therapeutic agents | |
| MXPA05008172A (es) | Derivados de malonamida como inhibidores gamma-secretasa. | |
| NO2007010I1 (no) | Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt | |
| EA200200306A1 (ru) | Трициклические ингибиторы поли(адф-рибозо)полимераз | |
| TNSN04165A1 (en) | Substituted hydroxyethylamines | |
| WO2001078711A3 (en) | Pde-v inhibitors for treatment of parkinson's disease | |
| CA2341031A1 (en) | Novel salt form of pantoprazole | |
| IL179634A0 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitor | |
| ATE535236T1 (de) | Therapeutische strategien für die prävention und behandlung der alzheimer-krankheit | |
| WO2003011274A3 (en) | Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma | |
| GB0112348D0 (en) | Compounds | |
| SE0202429D0 (sv) | Novel Compounds | |
| NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
| MXPA04006031A (es) | Compuestos para el tratamiento de trastornos inflamatorios. | |
| WO2002051832A3 (en) | Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands | |
| ATE552252T1 (de) | Isochinolinverbindungen und deren medizinische verwendung | |
| UY26851A1 (es) | Derivados de la 4-fenilpiridina | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| BR0113389A (pt) | Compostos que inibem a atividade do fator xa | |
| CA2443285A1 (en) | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis | |
| PL377715A1 (pl) | Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej | |
| NO20034301L (no) | Cyano-substituerte dihydropyrimidin forbindelser | |
| WO2002079149A3 (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |